Fig. 4: Matrix-M induces NLRP3 inflammasome activation and IL-1β release in vitro. | npj Vaccines

Fig. 4: Matrix-M induces NLRP3 inflammasome activation and IL-1β release in vitro.

From: Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization

Fig. 4

BMDCs were either non-primed (A) or LPS-primed (A–G) and treated with increasing doses of Matrix-M, Matrix-A, or Matrix-C for 5 hours. Released IL-1β levels were measured in the supernatants by ELISA. Before treatment with Matrix adjuvants, cells were pretreated for 1 h with no inhibitor (A–G), V-ATPase inhibitor bafilomycin A1 (BafA1) (B), cathepsin B inhibitor CA074-Me (C), NLRP3-related inhibitors MCC950 (D) and Ac-YVAD-cmk (F), or gasdermin D pore formation inhibitor disulfiram (G) at the indicated concentrations. Additionally, IL-1β levels were measured in NLRP3-deficient and wild-type (WT, C57BL/6) BMDCs after Matrix adjuvant treatment (E). Results are shown as the mean ± SD from at least three independent experiments.

Back to article page